ContraFect Competitors

Summary

ContraFect Corp competes with Palisade Bio, Allarity Therapeutics, Cns Pharmaceuticals, Windtree Therapeutics, and Quoin Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing ContraFect Corp competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ContraFect Corp to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of ContraFect Corp competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.00	0.00	0.00

Details

Intrinsic

Valuation

Low	Real	High
0.00	0.00	0.00

Details

ContraFect Corp Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ContraFect Corp and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of ContraFect and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ContraFect Corp does not affect the price movement of the other competitor.

	PALI	ALLR	CNSP	WINT	QNRX	REVB	VRAX	UNCY	NRBO
PALI		0.32	0.72	0.87	0.81	0.78	0.62	0.77	0.69	PALI
ALLR	0.32		0.39	0.17	0.06	0.06	0.2	0.09	0.15	ALLR
CNSP	0.72	0.39		0.72	0.56	0.59	0.61	0.59	0.48	CNSP
WINT	0.87	0.17	0.72		0.92	0.72	0.46	0.85	0.81	WINT
QNRX	0.81	0.06	0.56	0.92		0.82	0.46	0.87	0.81	QNRX
REVB	0.78	0.06	0.59	0.72	0.82		0.74	0.78	0.54	REVB
VRAX	0.62	0.2	0.61	0.46	0.46	0.74		0.46	0.31	VRAX
UNCY	0.77	0.09	0.59	0.85	0.87	0.78	0.46		0.69	UNCY
NRBO	0.69	0.15	0.48	0.81	0.81	0.54	0.31	0.69		NRBO
	PALI	ALLR	CNSP	WINT	QNRX	REVB	VRAX	UNCY	NRBO

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Risk-Adjusted Indicators

There is a big difference between ContraFect Stock performing well and ContraFect Corp Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ContraFect Corp's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Treynor Ratio	Potential Upside	Value @Risk	Maximum Drawdown
PALI	5.64	(0.47)	(2.59)	12.73	(11.84)	93.57
ALLR	5.22	(0.03)	0.45	13.24	(11.82)	47.01
CNSP	5.23	(0.60)	4.23	10.42	(10.84)	70.89
WINT	5.37	(3.19)	3.89	11.43	(13.33)	39.35
QNRX	5.68	(1.17)	1.34	14.29	(10.53)	57.78
REVB	5.43	(0.80)	(2.39)	11.78	(12.73)	66.25
VRAX	6.19	(0.27)	0.03	16.67	(11.98)	59.66
UNCY	3.93	(0.01)	(0.15)	7.69	(7.50)	28.72
NRBO	3.99	(0.35)	(0.54)	8.05	(7.34)	25.83

Unable to evaluate fundamental data of [PALI, ALLR, CNSP, WINT, QNRX, REVB, VRAX, UNCY, NRBO, HILS, FWBI, DRMA, PBLA] at this time. Please try again later

All Fundamental Data

ContraFect Corp Competitive Analysis

The better you understand ContraFect Corp competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ContraFect Corp's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ContraFect Corp's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	PALI	ALLR	CNSP	WINT	QNRX	REVB	VRAX	UNCY	NRBO	DRMA
	8.70 1.00 Palisade	6.67 0.96 Allarity	15.13 3.12 Cns	0.49 2.05 Windtree	3.45 0.30 Quoin	3.98 3.40 Revelation	6.20 1.37 Virax	1.72 0.59 Unicycive	5.50 1.89 NRBO	0.85 1.19 Dermata
Market Volatility (90 Days Market Risk)	Moderately volatile	Extremely Dangerous	Extremely Dangerous	Very risky	Abnormally volatile	Very risky	Very risky	Dangerous	Dangerous	Very risky
Market Performance (90 Days Performance)	Very Weak	Weak	Very Weak	Very Weak	Very Weak	Very Weak	Weak	Very Weak	Very Weak	Insignificant
Odds of Financial Distress (Probability Of Bankruptcy)	Very High	Very High	Very High	Very High	About Average	Very High	Below Average	Low	Dangerous	Very High
Current Valuation (Equity Enterprise Value)	Under Valued	Under Valued	Over Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Over Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Strong Buy	Hold	Buy	Hold	Strong Buy	Buy	Strong Sell	Strong Buy	Not Available	Buy
Trade Advice (90 Days Macroaxis Advice)	Strong Sell	Strong Sell	Cautious Hold	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Hold	Not Rated	Sell
Current Ratio	2.59	0.88	12.34	2.47	0.96	0.68	0.04	4.43	8.07	8.07
Net Asset	14.05 M	11.86 M	1.7 M	32.41 M	12.17 M	6.62 B	5.48 M	14.19 M	22.78 M	7.98 M
EBITDA	(12.28 M)	(12.08 M)	(18.86 M)	(20.16 M)	(9.27 M)	(7.98 B)	(6.61 M)	(30.18 M)	(15.88 M)	247.22 K
Current Valuation	(4.96 M)	(12.6 M)	(3.15 M)	1.25 M	(7.88 M)	(3.54 M)	(515.46 K)	28.9 M	(1.18 M)	178.9 K
Price To Book	0.41	0.35	1.13	0.35	0.45	0.63	0.74	2.17	1.57	1.33
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-581.12	N/A	N/A	N/A
Retained Earnings	(121.51 M)	(94.45 M)	(69.57 M)	(844.82 M)	(46.2 M)	(40.51 B)	(18.53 M)	(64.54 M)	(108.27 M)	(53.39 M)
Current Asset	N/A	N/A	6.61 M	40.79 M	N/A	N/A	N/A	N/A	21.62 M	N/A
Beta	1.41	0.29	1.05	0.64	1.59	0.18	1.59	2.25	-0.28	0.65
Number Of Employees	9	5	3	N/A	4	9	17	14	8	8
Shares Outstanding	2.77 M	1.41 M	40.75 M	8.75 M	8.19 M	905.23 K	4.34 M	103.8 M	8.62 M	5.36 M
Cash Flow From Operations	(11.13 M)	(12.74 M)	(14.14 M)	(13.44 M)	(7.86 M)	(18.32 B)	(6.25 M)	(18.28 M)	(10.8 M)	(6.41 M)
Total Debt	369 K	1.3 M	300.81 K	16.83 M	3.52 K	1.91 B	224.3 K	811 K	203 K	1.62 M
Return On Equity	-1.36	-1.22	-10.19	-1.51	-1.35	-2.65	-0.91	-1.47	-1.61	-2.02
Z Score	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return On Asset	-0.68	-0.48	-2.24	-0.45	-0.44	-0.53	-0.48	-0.63	-0.74	-1.03
Number Of Shares Shorted	106.91 K	635.61 K	3.93 M	2.87 M	44.39 K	89.49 K	180.39 K	795.15 K	34.27 K	277.97 K
Book Value Per Share	5.51	16.98	-2.97	5.9	1.08	9.02	1.99	0.28	1.51	2.83
Current Liabilities	N/A	N/A	488.66 K	11.07 M	N/A	N/A	N/A	N/A	11.75 M	N/A
Total Asset	14.05 M	11.86 M	1.7 M	32.41 M	12.17 M	6.62 B	5.48 M	14.19 M	22.78 M	7.98 M
Debt To Equity	0.23	0.11	0.013	0.95	0.47	0.009	N/A	0.023	0.005	N/A
Short Ratio	0.96	0.3	0.04	0.06	0.26	0.37	0.7	1.4	0.87	1.17
Target Price	20.0	5.0	0.5	7.0	4.48	170.73	20.0	5.5	26.67	6.0
Shares Owned By Institutions	7.2	1.2	0.7	0.59	18.89	6.8	6.72	60.39	12.71	0.85
Market Capitalization	2.72 M	2.06 M	5.28 M	4.92 M	2.42 M	2.96 M	5.6 M	60.44 M	20.33 M	6.32 M
Price To Earning	0.16	N/A	-13.7	-0.05	N/A	8.69	N/A	N/A	-1.44	N/A
Price To Sales	14.03	N/A	N/A	660.53	N/A	2.88	66.0	62.82	N/A	N/A
Net Income	(12.3 M)	(11.9 M)	(18.85 M)	(20.29 M)	(8.69 M)	(15.04 B)	(6.74 M)	(30.54 M)	(12.47 M)	(7.79 M)
Earnings Per Share	-13.26	-10.98	-352.97	-19.03	-3.66	-87.68	-2.61	-0.46	-4.29	-13.36
Shares Owned By Insiders	0.79	12.3	1.2	0.27	16.57	N/A	6.63	6.12	65.23	23.58
Revenue	250 K	N/A	N/A	N/A	N/A	N/A	156.42 K	675 K	7 K	N/A
Working Capital	10.74 M	(12.2 M)	(4.54 M)	1.38 M	7.7 M	4.65 M	4.21 M	(4.13 M)	16.55 M	6.36 M
Cash And Equivalents	5 M	7.73 M	8.96 M	11.38 M	2.69 M	3.48 M	21.76 K	10.57 M	8.85 M	10.63 M
Cash Per Share	0.23	0.75	0.22	0.37	0.56	0.15	N/A	0.7	9.96	1.05
Gross Profit	N/A	(36.35 M)	N/A	(17.79 M)	N/A	90.91 M	33.6 K	N/A	N/A	N/A
Day Typical Price	1.02	0.94	3.07	2.04	0.3	3.37	1.36	0.59	1.88	1.18
Accumulation Distribution	198884.0	103228.0	62773.98	2081.2	19194.52	568.64	8730.68	13357.5	0.13	3428.75
Market Facilitation Index	N/A	N/A	0.0	0.0	N/A	0.0	0.0	N/A	0.25	0.0
Daily Balance Of Power	0.5333	0.5455	0.6613	(0.08)	0.5	0.7222	0.6667	0.3333	(0.44)	0.1667
Period Momentum Indicator	0.08	0.06	0.41	(0.01)	0.01	0.13	0.08	0.01	(0.11)	0.01
Rate Of Daily Change	1.09	1.07	1.15	1.0	1.03	1.04	1.06	1.02	0.95	1.01
Day Median Price	1.02	0.93	3.04	2.04	0.3	3.36	1.36	0.59	1.88	1.17
Price Action Indicator	0.015	0.065	0.29	0.005	0.005	0.1	0.05	0.01	(0.04)	0.025
Coefficient Of Variation	(2,222)	(64,758)	(1,477)	(243.56)	(772.27)	(1,045)	(28,950)	(3,708)	(1,152)	4328.04
Mean Deviation	5.64	5.22	5.23	5.37	5.68	5.43	6.19	3.93	3.99	4.33
Jensen Alpha	(0.47)	(0.03)	(0.60)	(3.19)	(1.17)	(0.80)	(0.27)	(0.01)	(0.35)	0.1649
Total Risk Alpha	1.33	1.24	0.8432	(1.82)	0.3063	0.6318	1.52	0.7108	0.4298	1.15
Sortino Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0484
Downside Variance	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	31.54
Standard Deviation	10.84	7.48	8.46	7.46	8.11	8.81	9.28	5.09	5.38	6.04
Kurtosis	25.58	4.08	9.41	1.09	3.79	8.86	5.27	1.29	2.05	1.91
Potential Upside	12.73	13.24	10.42	11.43	14.29	11.78	16.67	7.69	8.05	12.26
Treynor Ratio	(2.59)	0.4548	4.23	3.89	1.34	(2.39)	0.0259	(0.15)	(0.54)	0.5239
Maximum Drawdown	93.57	47.01	70.89	39.35	57.78	66.25	59.66	28.72	25.83	35.54
Variance	117.5	56.02	71.61	55.72	65.71	77.61	86.12	25.94	28.96	36.54
Market Risk Adjusted Performance	(2.58)	0.4648	4.24	3.9	1.35	(2.38)	0.0359	(0.14)	(0.53)	0.5339
Risk Adjusted Performance	(0.03)	0.0076	(0.05)	(0.34)	(0.10)	(0.07)	0.0062	(0.01)	(0.06)	0.0281
Skewness	3.87	1.17	(1.13)	0.1691	0.2687	1.79	1.6	0.7111	0.2992	0.4709
Semi Deviation	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	5.06
Information Ratio	(0.03)	0.0161	(0.05)	(0.39)	(0.11)	(0.08)	0.0108	(0.001)	(0.06)	0.045
Value At Risk	(11.84)	(11.82)	(10.84)	(13.33)	(10.53)	(12.73)	(11.98)	(7.50)	(7.34)	(7.35)
Expected Short fall	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	(5.43)
Downside Deviation	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	5.62
Semi Variance	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	25.59

ContraFect Corp Competition Performance Charts

Five steps to successful analysis of ContraFect Corp Competition

ContraFect Corp's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ContraFect Corp in relation to its competition. ContraFect Corp's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of ContraFect Corp in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ContraFect Corp's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ContraFect Corp, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ContraFect Corp position

In addition to having ContraFect Corp in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Size And Style ETFs Thematic Idea Now

Size And Style ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Size And Style ETFs theme has 1205 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Size And Style ETFs Theme or any other thematic opportunities.

View All Next

Launch

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Consideration for investing in ContraFect Stock

If you are still planning to invest in ContraFect Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ContraFect Corp's history and understand the potential risks before investing.

	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC